PUrE: percutaneous nephrolithotomy, flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole kidney stones

Submission date	Recruitment status No longer recruiting	Prospectively registered		
11/11/2015		[X] Protocol		
Registration date 11/11/2015	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 19/08/2025	Condition category Urological and Genital Diseases	Individual participant data		

Plain English summary of protocol

Background and study aims

Kidney stones are stone-like lumps that can develop in one or both of the kidneys. Although some stones do not cause pain or discomfort, patients can develop serious pain, infection, blood in urine, kidney problems or even kidney failure. Many stones occur in the lower part of the kidney (lower pole stones). These stones are more likely to require treatment because they are less likely to pass on their own. Currently within the NHS there are three treatment options for lower kidney stones: extracorporeal shockwave lithotripsy (ESWL), percutaneous nephrolithotomy (PNL), and flexible ureterorenoscopy with laser lithotripsy (FURS). We are uncertain which of these treatments is best at getting rid of stones and which is best value for patients and the NHS. They each have advantages and disadvantages (benefits and harms). The aim of this study is to determine the clinical effectiveness and cost effectiveness of these three treatment options for lower kidney stones.

Who can participate?

Patients aged 16 or over with lower pole kidney stones.

What does the study involve?

Patients with smaller stones are randomly allocated to be treated with either FURS or ESWL. Patients with larger stones are randomly allocated to be treated with either FURS or PCNL. In FURS, a small telescope is passed into the bladder through the urethra and up to the kidney, and a laser beam breaks the stone into pieces, which are then either retrieved or the passed spontaneously after the procedure. In ESWL, shockwaves from a machine outside the body target and break the stone into pieces, which are then passed spontaneously. In PCNL, a hole is made in the skin, a tube is inserted through it into the kidney, and a small telescope is inserted into the kidney via the tube to break the stone and remove all the pieces.

What are the possible benefits and risks of participating?

Patients undergoing FURS require an anaesthetic and sometimes a hospital stay, and there is a

small risk of complications (e.g., infection, bleeding). ESWL does not need an anaesthetic nor hospital stay, but passing the pieces can take time, more than one treatment may be needed for larger stones, and some pieces may not pass at all. PCNL usually clears the stone completely in one go, but needs an anaesthetic, hospital stay, and may cause more serious problems (bleeding and infection). We think FURS may clear the stone more efficiently than ESWL, but less well than PNL.

Where is the study run from? Aberdeen Royal Infirmary (UK) and 48 hospitals across the UK (as of 29/10/2018)

When is the study starting and how long is it expected to run for? May 2015 to February 2023

Who is funding the study? National Institute for Health Research Technology Assessment Programme (NIHR HTA) (UK).

Who is the main contact?

Dawn McRae, pure@abdn.ac.uk

Contact information

Type(s)

Scientific

Contact name

Prof Samuel McClinton

Contact details

NHS Grampian
Department of Urology
Aberdeen Royal Infirmary
Foresterhill
Aberdeen
United Kingdom
AB25 2ZB

Type(s)

Public

Contact name

Ms Dawn McRae

Contact details

PUrE Trial Office Centre for Healthcare Randomised Trials (CHaRT) 3rd Floor Health Sciences Building University of Aberdeen Foresterhill Aberdeen United Kingdom AB25 2ZB

Additional identifiers

Clinical Trials Information System (CTIS)

2014-002751-25

Integrated Research Application System (IRAS)

188563

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

HTA 13/152/02, IRAS 188563

Study information

Scientific Title

The clinical and cost effectiveness of surgical interventions for stones in the lower pole of the kidney: the percutaneous nephrolithotomy, flexible ureterorenoscopy and extracorporeal lithotripsy for lower pole kidney stones randomised controlled trial (PUrE RCT)

Acronym

PUrE

Study objectives

The null hypotheses being tested are:

- 1. The use of flexible urterorenoscopy with laser lithotripsy (FURS) to treat lower pole kidney stones less than 10 mm will not be superior to extracorporeal shockwave lithotripsy (ESWL) as assessed by a relative increase of at least 0.3 of a standard deviation (SD) on the EQ-5D AUC up to 12 weeks post treatment
- 2. The use of FURS to treat lower pole stones of the kidney 10 mm or greater and less than or equal to 25 mm will not be superior to percutaneous nephrolithotomy (PCNL) by an increase of 0.3SD on the EQ-5D AUC up to 12 weeks post treatment.

Further information can be found at: http://www.nets.nihr.ac.uk/projects/hta/1315202

Ethics approval required

Old ethics approval format

Ethics approval(s)

North of Scotland Research Ethics Committee, 10/11/2015, REC ref: 15/NS/0113

Study design

Two separate pragmatic multicentre patient-randomised open-label superiority randomised controlled trials with an initial internal pilot phase

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Lower pole kidney stones

Interventions

RCT 1: FURS versus ESWL for stone sizes <=10 mm

RCT 2: FURS versus PCNL for stone sizes >10mm <=25 mm

FURS

A flexible ureteroscope is passed into the kidney and a holmium laser fibre used to fragment stones. Stone fragments are then either retrieved or the patient passes them spontaneously after the procedure.

PCNL

A small incision is made in the skin through which a tube is inserted into the kidney. A nephroscope is inserted via this tube to retrieve the stone, or fragment it before retrieval. The intention is to remove all stone fragments.

ESWL

An external acoustic pulse (shockwave), from outside the body is focused onto the kidney stone, causing it to fragment. Stone fragments are then passed spontaneously by the patient in the days following the treatment. It may be delivered by fixed (static, on-site) or mobile (external) machines.

Intervention Type

Procedure/Surgery

Primary outcome(s)

- 1. Patient-reported: Health status (EQ-5D-5L) area under the curve (AUC) to 12 weeks post intervention, based upon EQ-5D completion at fixed time points; at baseline (recruitment), just prior to initial intervention (FURS, PCNL or first session of ESWL), at 1, 2, 4, 8, and 12 weeks after initial intervention, and at variable time points; just prior and 1 week after any additional intervention (including planned additional ESWL sessions and removal of stent) and once during hospitalisation for adverse events related to treatment (e.g. pain and infection).
- 2. Economic: Incremental cost per quality adjusted life year (QALYs) gained at 12 months post-randomisation based on the estimated NHS costs and participant responses to the EQ-5D (including additional time point at 12 months).

Key secondary outcome(s))

- 1. Patient reported:
- 1.1. Severity of pain as measured by the Numeric Rating scale (NRS; completed with EQ-5D-5L)
- 1.2. Generic health profile as measured by the SF-12 (completed at baseline and 12 months)
- 1.3. Use of analgesia (completed with NRS and EQ-5D)
- 2. Clinical:
- 2.1. Stone clearance measured at between 8 and 12 weeks post initial intervention using renal imaging (CTKUB preferred but plain x-ray and ultrasound acceptable). Measured by local trial staff and categorized as complete, acceptable, or unacceptable. Also maximum dimension of the

largest fragment of the treated stone in mm

- 2.2. Need for additional treatment (carried out or planned) at 12 weeks post-initial treatment and 12 months post randomisation
- 2.3. Complications during initial intervention. Intervention-related complications at 12 weeks (categorised by Clavien-Dindo classification) post treatment and up to 12 months post randomisation. All measured by site staff and entered on CRF.
- 3. Economic:
- 3.1. NHS primary and secondary care resources used and their costs
- 3.2. Patient costs (out of pocket), time off work up to 12 months post randomisation Data gathered from completion of CRFs by site staff and participant questionnaire at 12 weeks post initial treatment and 12 months post randomisation.

Completion date

28/02/2023

Eligibility

Key inclusion criteria

- 1. Adults ≥16 years of age
- 2. Lower pole stone ≤25 mm in maximum dimension with decision to treat that stone
- 3. Presence of stone confirmed by CTKUB
- 4. Able and willing to undergo either treatment for specified stone size
- 5. Capacity to give informed consent to participate in trial which includes adherence to trial requirements

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

625

Key exclusion criteria

- 1. Pregnancy
- 2. Patients with co-existing stone that takes precedence in deciding treatment modality (such as obstructing ureteric stone or large upper pole stone)
- 3. Patients with health or other factors that are absolute contraindications to an intervention that they may be allocated
- 4. Patients unable to understand or complete trial documentation

Date of first enrolment

01/05/2015

Date of final enrolment

31/03/2021

Locations

Countries of recruitment

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre Aberdeen Royal Infirmary

Department of Urology Ward 44 Foresterhill Aberdeen United Kingdom AB25 2ZB

Study participating centre Norfolk and Norwich University Hospital

Colney Lane Norwich United Kingdom NR4 7UY

Study participating centre Pinderfields Hospital

Aberford Road Wakefield United Kingdom WF1 4DG

Study participating centre Freeman Hospital Freeman Road

High Heaton

Newcastle upon Tyne United Kingdom NE7 7DN

Study participating centre Addenbrooke's Hospital

Hills Road Cambridge United Kingdom CB2 0QQ

Study participating centre Broomfield Hospital

Court Road
Broomfield
Chelmsford
United Kingdom
CM1 7ET

Study participating centre Royal Blackburn Hospital

Haslingden Road Blackburn United Kingdom BB2 3HH

Study participating centre Southampton General Hospital

Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre Southmead Hospital

Dorian Way Westbury-on-Trym Bristol United Kingdom BS10 5NB

Study participating centre Churchill Hospital

Old Road Headington Oxford United Kingdom OX3 7LE

Study participating centre Charing Cross Hospital

Fulham Palace Road London United Kingdom W6 8RF

Study participating centre Raigmore Hospital

Old Perth Road Inverness United Kingdom IV2 3UJ

Study participating centre Arrowe Park Hospital

Arrowe Park Road Upton Birkenhead Wirral United Kingdom CH49 5PE

Study participating centre James Cook University Hospital

Marton Road Middlesborough United Kingdom TS4 3BW

Study participating centre

Royal Hallamshire Hospital

Glossop Road Sheffield United Kingdom S10 2JF

Study participating centre Royal Oldham Hospital

Rochdale Road Manchester United Kingdom OL1 2JH

Study participating centre Belfast City Hospital

Lisburn Road Belfast United Kingdom BT9 7AB

Study participating centre Wrexham Maelor Hospital

Croesnewydd Road Wrexham United Kingdom LL13 7TD

Study participating centre Derriford Hospital

Derriford Road Plymouth United Kingdom PL6 8DH

Study participating centre St James's University Hospital

Beckett Street Leeds United Kingdom LS9 7TF

Study participating centre Manchester Royal Infirmary

Grafton Street Manchester United Kingdom M13 9WL

Study participating centre Salford Royal Hospital

Stott Lane Salford United Kingdom M6 8HD

Study participating centre Royal Bournemouth Hospital

Castle Lane E Bournemouth United Kingdom BH7 7DW

Study participating centre Sunderland Royal Hospital

Kayll Road Sunderland United Kingdom SR4 7TP

Study participating centre Kingston Hospital

Galsworthy Road Kingston upon Thames United Kingdom KT2 7QB

Study participating centre Wythenshawe Hospital Southmoor Road

Wythenshawe

Manchester United Kingdom M23 9LT

Study participating centre Stockport NHS Foundation Trust

Stepping Hill Hospital Poplar Grove Hazel Grove Stockport United Kingdom SK2 7JE

Study participating centre Eastbourne District General Hospital

King's Drive Eastbourne United Kingdom BN21 2UD

Study participating centre Western General Hospital

Department of Urology Western General Hospital Crewe Road South Edinburgh United Kingdom EH4 2XU

Study participating centre Southport & Formby District General Hospital

Town Lane Southport United Kingdom PR8 6PN

Study participating centre Kent and Canterbury Hospital

Ethelbert Road

Canterbury United Kingdom CT1 3NG

Study participating centre St Helens and Knowsley Teaching Hospitals

Whiston Hospital
Warrington Road
Rainhill
Prescot
United Kingdom
L35 5DR

Study participating centre Broadgreen Hospital

Thomas Drive Liverpool United Kingdom L14 3LB

Study participating centre Epsom General Hospital

Dorking Road Epsom United Kingdom KT18 7EG

Study participating centre Dartford and Gravesham NHS Trust

Darenth Wood Road Dartford United Kingdom DA2 8DA

Study participating centre Rotherham NHS Foundation Trust

Moorgate Road Rotherham United Kingdom S60 2UD

Study participating centre Royal Sussex County Hospital

Barry Building Eastern Road Brighton United Kingdom BN2 5BE

Study participating centre St George's, University of London

Cranmer Terrace London United Kingdom SW17 ORE

Study participating centre Northwick Park Hospital

Watford Road Harrow United Kingdom HA1 3UJ

Study participating centre Victoria Hospital

Pettits Lane Romford United Kingdom RM1 4HL

Study participating centre Gloucestershire Hospitals NHS Foundation Trust

Alexandra House Cheltenham General Hospital Sandford Road Cheltenham United Kingdom GL53 7AN

Study participating centre

University Hospitals Coventry & Warwickshire

Clifford Bridge Road Coventry United Kingdom CV2 2DX

Study participating centre Western Sussex Hospitals

Western Sussex Hospitals NHS Foundation Trust Spitalfield Lane Chichester United Kingdom PO19 6SE

Study participating centre Bradford Teaching Hospitals NHS Foundation Trust

Duckworth Lane Bradford United Kingdom BD9 6RJ

Study participating centre Blackpool Teaching Hospitals NHS Foundation Trust

Trust Headquarters
Blackpool Victoria Hospital
Whinney Heys Road
Blackpool
United Kingdom
FY3 8NR

Study participating centre

Ashford & St. Peter's Hospitals NHS Foundation Trust

Ashford Hospital London Road Ashford United Kingdom TW15 3AA

Study participating centre Royal Devon & Exeter NHS Foundation Trust Barrack Road Exeter United Kingdom EX2 5DW

Study participating centre Royal Berkshire NHS Foundation Trust

London Road Craven Road Reading United Kingdom RG1 5AN

Study participating centre Royal Cornwall Hospitals NHS Trust

Penventinnie Lane Truro United Kingdom TR1 3LJ

Study participating centre University Hospitals of Leicester NHS Trust Gwendolen Road

Leicester
United Kingdom
LE5 4PW

Sponsor information

Organisation

University of Aberdeen (UK)

Organisation

Grampian Health Board (UK)

Funder(s)

Funder type

Funder Name

National Institute for Health Research Technology Assessment Programme (NIHR HTA)

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		22/04/2025	27/05/2025	Yes	No
Results article		01/08/2025	19/08/2025	Yes	No
<u>Protocol article</u>	protocol	04/06/2020	08/06/2020	Yes	No
HRA research summary			28/06/2023	No	No
Other publications		13/03/2025	27/05/2025	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes